 |
      
|
|
|
|
|
|||||
|
|
February 23, 2006
Neurochem to report on fourth quarter and fiscal year 2005 About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics to addresses critical unmet
medical needs. Eprodisate (Fibrillex™) is designated as an orphan drug, is a Fast Track product candidate and
is also part of the FDA Continuous Marketing Application Pilot 1 and Pilot 2 programs. The Phase II/III clinical
trial of Fibrillex™ for the treatment of AA amyloidosis was concluded in April 2005. The Company has completed
its submission of a New Drug Application for Fibrillex™ that the FDA agreed in June 2005 to file and review.
Tramiprosate (Alzhemed™), for the treatment of Alzheimer's disease, is currently in Phase III clinical trials in
both North America and Europe and tramiprosate (Cerebril™), for the prevention of Hemorrhagic Stroke caused by
Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial. To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable
at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which
are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which
Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, as well as other risks disclosed in public filings of Neurochem. Consequently, actual future
results may differ materially from the anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance, if any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update
or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information
Form for further risk factors that might affect the Company and its business.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
